-
There are "benefits" for asthma?
Time of Update: 2021-12-29
▲T cells activated by asthma can help inhibit the activation of brain microglia (picture source: reference [1]) Based on this mechanism, researchers have proposed a new strategy for the treatment of visual pathway glioma .
-
The EAU guidelines newly recommend the first immune adjuvant therapy after renal cancer surgery: there are "4+5" reasons you have to know
Time of Update: 2021-12-29
After using the modified GRADE method to assess the quality of evidence and the strength of the recommendation, the EAU RCC guideline expert group reached a consensus and recommended (weak): Pembrolizumab is recommended for the adjuvant treatment of high-risk (according to the study definition) operable ccRCC patients (at least the final OS After the data is available) .
-
Molecular Cancer Sichuan University Peng Yong/Zhu Xiaofeng/Zhou Liangxue systematically characterized the genetic change spectrum of craniopharyngioma
Time of Update: 2021-12-29
On December 18, 2021, Peng Yong, Zhu Xiaofeng, and Zhou Liangxue of Sichuan University published an online research paper entitled "Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing" in Molecular Cancer (IF=27).
In addition, the study confirmed that CTNNB1 and BRAF V600E mutations are mutually exclusive in ACP and PCP, respectively .
-
Molecular Pathology Detection of Lung Cancer in China
Time of Update: 2021-12-28
"The molecular variation spectrum of NSCLC patients in China is different from the Western population. It is mainly manifested in lung adenocarcinoma. Which are the mandatory genes? Which are the e
-
Cancer therapy has a new trick!
Time of Update: 2021-12-28
A recent study published in "Cell Reports" entitled "Pan-cancer analysis reveals molecular patterns associated with age" shows that there are significant differences in the molecular characteristics of tumors in patient groups of different ages, and that young patients and elderly patients should be looked at Work is suffering from different diseases and undergoing different treatments .
-
Courier reduces the mortality of bladder cancer patients by 30%!
Time of Update: 2021-12-28
▎The content team editor of WuXi AppTec recently, Astellas Pharma and Seagen jointly announced that the European Medicines Agency (EMA) Committee for Human Medicines (CHMP) has issued positive opinions and recommends the approval of antibody-conjugated drugs (ADC) Padcev (enfortumab vedotin) is used as a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
-
Express targets a variety of solid tumors, and clinical trials of allogeneic CAR-T therapy have been approved by the FDA
Time of Update: 2021-12-28
▎ WuXi AppTec content team editor today, Poseida Therapeutics announced that the US FDA has approved a new drug clinical trial application (IND) for the allogeneic CAR-T cell therapy P-MUC1C-ALLO1 to treat multiple solid tumor indications .
-
Molecular Cancer Chen Jinhong's team at Fudan University has developed a new method for large-scale cancer detection
Time of Update: 2021-12-28
In conclusion, this study reveals the value of serum circulating m6A miRNA in cancer detection, and provides a new direction and strategy for the development of new biomarkers with high precision, low cost and low invasiveness for large-scale cancer screening .
-
CStone Pharmaceuticals announces that Zejiemei® (suglimumab injection) has been approved for marketing in China, which is expected to reshape the landscape of lung cancer immunotherapy
Time of Update: 2021-12-28
The PD-L1 antibody Zejiemei® was approved for the first-line treatment of patients with metastatic non-small cell lung cancer in combination with chemotherapy. -L1 antibody Zejiemei® is under review
-
"Nature-Nanotechnology": Adding a little nanoparticle can greatly enhance the effect of anti-cancer therapy
Time of Update: 2021-12-28
According to the research published by him and his colleagues in Nature Nanotechnology, some clinical trials are currently adopting immune checkpoint inhibitors and some new immunotherapies to help treat MPE.
-
Good news spreads frequently, the domestically developed PD-1 carrelizumab has been approved as a new first-line indication for advanced esophageal cancer!
Time of Update: 2021-12-28
In 2019, a landmark study in the field of esophageal cancer immunotherapy-ESCORT research achieved breakthrough success, and Carrelizumab was approved as a second-line treatment indication for esophageal squamous cell carcinoma .
-
Nature anti-HER2 and PD-1 dual-pronged treatment of gastric cancer
Time of Update: 2021-12-28
A few years ago, the combined intervention of anti-HER2 antibody drug trastuzumab (trastuzumab) and chemotherapy has become clinically the first-line treatment for gastric cancer [4] .
-
A team of Chinese scientists in basic research: Baicalein is expected to be used in a new type of targeted therapy for colorectal cancer
Time of Update: 2021-12-27
In this study, the researchers used colorectal cancer cells as a research model, conducted drug-target-disease network analysis, and constructed a protein-protein interaction network to explore the downstream of TLR4 that mediates the inhibitory effect of baicalein Signal molecule .
-
Nat Commun: Dong Yizhou's team developed biomimetic nanoparticles to deliver mRNA to enhance cancer immunotherapy
Time of Update: 2021-12-26
Nature Communications Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapyThe research team discovered that a phospholipid-derived nanoparticle, PL1, can effectively deliver mRNA to T cells in vivo and in vitro .
-
J Hepatol: Efficacy update of Atezolizumab combined with bevacizumab vs sorafenib in the treatment of unresectable hepatocellular carcinoma: IMbrave150
Time of Update: 2021-12-26
IMbrave150 is a phase III open-label clinical study that mainly evaluates the efficacy and safety of PD-L1 inhibitor atezolizumab combined with bevacizumab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma ( HCC ) .
-
Am J Clin Nutr: Eating less meat and more vegetarian food can greatly reduce the risk of prostate cancer!
Time of Update: 2021-12-25
In men <65 years of age, a higher plant-based diet index is associated with a lower risk of advanced, fatal prostate cancer .
-
JAMA Oncol: A new adjuvant therapy for locally advanced colorectal cancer-radiotherapy and chemotherapy + induction/consolidation chemotherapy!
Time of Update: 2021-12-25
5445Induction or Consolidation Chemotherapy Plus Chemoradiotherapy AS Neoadjuvant the Total Therapy for Patients With Locally Advanced Rectal Cancer: Results of Long-Term The CAO / ARO / 12 is the AIO-Randomized Clinical Trial JAMA in this message
-
Cancers: Comparison of the efficacy of surgery and radiofrequency ablation (RFA) in the treatment of patients with hepatitis B-related hepatocellular carcinoma
Time of Update: 2021-12-25
Studies have shown that radiofrequency ablation (RFA) in patients with early hepatocytes has an OS equivalent to surgical resection, but RFS is shorter than surgical resection .
-
Journal of Vascular Surgery: The prognostic effect of vascular calcification on the progression of abdominal aortic aneurysm
Time of Update: 2021-12-25
The log-linear mixed model of AAA growth prediction takes time as the main influencing factor, and the effect of changes in vascular calcificationSummarizeSummarizeThe investigators evaluated the prognostic value of vascular calcification measured by CTA on the progression of AAA .
-
JCEM: The relationship between oral contraceptives and menopausal hormone therapy and the risk of pituitary adenoma
Time of Update: 2021-12-25
Currently, there are no prospective epidemiological studies evaluating the association between the use of oral contraceptives (OC) or menopausal hormone therapy (MHT) and the risk of female pituitary adenomas .
